<DOC>
	<DOCNO>NCT00824746</DOCNO>
	<brief_summary>A single arm , open label , prospective , phase II trial Gefitinib retreatment advance metastatic ( IIIb IV ) NSCLC patient previously respond gefitinib And progressive disease observe least one prior regimen follow previous gefitinib failure . Primary endpoint - assess Disease Control Rate ( Remission + Stable disease ) Secondary endpoint - ass progression free survival</brief_summary>
	<brief_title>Study Gefitinib Retreatment Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Recurrent progressive NonSmall Cell Lung Cancer ( NSCLC ) stage IV IIIB patient chemotherapy follow gefitinib failure Male female patient age 18 year World Health Organization ( WHO ) performance status 02 ( performance status 2 must stable deterioration previous 2 week ) Had least stable disease previous Gefitinib treatment Had least one anticancer agent therapy gefitinib failure ; Following treatment another epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKIs ) erlotinib TKIs include anticancer agent therapy . The current approved indication Gefitinib 2nd 3rd line monotherapy recurrent metastatic NSCLC . However , practice offlabel indication , also use 1st line treatment patient 's expense . Thus , trial gefitinib retreatment 3rd line . Measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) least one measurable lesion previously irradiate , unless disease progression document site . Provision write informed consent Life expectancy least 12 week Evidence clinically active Interstitial Lung Diseases ( Patients chronic , stable , radiographic change asymptomatic need exclude ) Expected life expectancy le 2 month Known severe hypersensitivity gefitinib excipients product Any unresolved chronic toxicity great Common Terminology Criteria ( CTC ) grade 2 previous anticancer therapy As judged investigator , evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , cardiac , hepatic , renal disease ) Serum bilirubin great 3 time upper limit reference range ( ULRR ) Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) ≥ 2.5 x Upper Limit Normal ( ULN ) demonstrable liver metastasis ( &gt; 5 x presence liver metastasis ) Evidence significant clinical disorder laboratory find make undesirable subject participate study Pregnancy breastfeed woman ( woman child¬bearing potential ) . Women childbearing potential must practice acceptable method birth control prevent pregnancy . Newly diagnosed central nervous system ( CNS ) metastases yet treat surgery and/or radiation . Patients previously diagnose treat CNS metastases spinal cord compression may consider evidence clinically stable disease ( steroid therapy steroid dose taper ) least 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Gefitinib</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
</DOC>